Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | 圖書 |
| 出版: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| 主題: | |
| 在線閱讀: | Connect to this object online. |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
| 索引號: |
A1234.567 |
|---|---|
| 復印件 1 | 可用 |